Imatinib mesylate-induced generalized hypopigmentation in patients with chronic myeloid leukemia

Indian Journal of Pharmacology

Volumn 38, Issue 1, 2006, Pages 66-67

  Sunita, ^a   Gupta, D K ^a   Saluja, S ^a   Bhasin, S ^a   Sharma, M ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; INTERFERON;

ADULT; ARTHRALGIA; ARTICLE; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOPIGMENTATION; MALE; SKIN BIOPSY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33344459150     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.19860     Document Type: Article

References (4)

1. Hasan S, Dinh K, Lombardo F, Dawkins F, Kark J. Hypopigmentation in an African patient treated with imatinib mesylate: A case report. J Natl Med Assoc 2003;95:722-4.
2. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81.
3. Sharma A, Vora A, Bhutani M. Generalized hypopigmentation due to imatinib: a fairness boon? Indian J Dermatol Venereol Leprol 2005;71:45-6.
4. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.